Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

FOUND: Sanofi drug shows superior efficacy in genetic disease compared to current standard therapy - What They Never Told You

Gentilly,,France,,March,21,,2021:,Sign,And,Logo,On,The

Sanofi SA (NASDAQ:SNY) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101), for alpha-1 antitrypsin deficiency (AATD) emphysema.

AATD causes emphysema when the body doesn’t produce enough of the protective alpha-1 antitrypsin (AAT) protein, leading to a breakdown of the lung’s air sacs (alveoli).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.